Rituximab in thrombotic primary antiphospholipid syndrome: a pilot study from a single centre in China

Ann Rheum Dis. 2021 Jun;80(6):820-822. doi: 10.1136/annrheumdis-2020-219303. Epub 2021 Jan 15.

Authors

Yijun You^#¹, Ce Shi^#², Zhuochao Zhou¹, Fan Wang¹, Yue Sun¹, Jialin Teng¹, Honglei Liu¹, Xiaobing Cheng¹, Yutong Su¹, Hui Shi¹, Chengde Yang³, Junna Ye³

Affiliations

¹ Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
² Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
³ Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China yjn0912@qq.com yangchengde@sina.com.

^# Contributed equally.

PMID: 33452001
DOI: 10.1136/annrheumdis-2020-219303

No abstract available

Keywords: antibodies; antiphospholipid; antiphospholipid syndrome; rituximab.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Antiphospholipid
Antiphospholipid Syndrome* / complications
Antiphospholipid Syndrome* / drug therapy
Humans
Pilot Projects
Rituximab / therapeutic use
Thrombosis* / drug therapy
Thrombosis* / etiology

Substances

Antibodies, Antiphospholipid
Rituximab